Date: 2021/3/2
Your Name:Haifeng Yu
Manuscript Title: Bruton's Tyrosine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tumor Efficacy and Brain Distribution
Manuscript number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	frame: Since the initial planning ofNone Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.  Payment made to the institution.
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past 36 monthsV_NoneV_None	

4	Consulting fees	_v_None	
_			
5	Payment or honoraria for	V_None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√ None	
"	r dyment for expert testimony		
7	Support for attending	_v_None	
	meetings and/or travel		
8	Patents planned, issued or	V_None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or	v_None	
	Advisory Board		
10	Leadership or fiduciary role in	√ None	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		
11	Stock or stock options	_v_None	
12	Receipt of equipment,	V_None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	√ None	
13	financial interests	v_ivorie	
	inianciai interests		

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

### Please place an "X" next to the following statement to indicate your agreement:

Date:	2021/3/2
Your Na	me:Haiying Kong
Manuscr	ipt Title: Bruton's Tyrosine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tum	nor Efficacy and Brain Distribution
Manuscr	ript number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time fram	e: Since the initial planning of the w	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.  Payment made to the institution.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	V_None	
3	Royalties or licenses	_V_None	
4	Consulting fees	_v_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_V_None	
	manuscript writing or educational events		
6	Payment for expert testimony	V_None	
7	Support for attending meetings and/or travel	_V_None	
8	Patents planned, issued or pending	_v_None	
9	Participation on a Data	_v_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	_v_None	
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
12	Receipt of equipment, materials,	_v_None	
13		v None	
13			
13	drugs, medical writing, gifts or other services  Other financial or non-financial interests	v_None	

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

### Please place an "X" next to the following statement to indicate your agreement:

Date:_	2021/3/2
Your N	ame:Cong Li
Manus	cript Title: Bruton's Tyrosine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tu	mor Efficacy and Brain Distribution
Manus	cript number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Time	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NoneNone Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.  Payment made to the institution.
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past 36 months √ _None √ _None	
4	Consulting fees	√ _None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	√ _None √ _None	
7	Support for attending meetings and/or travel	_ √ _None	
8	Patents planned, issued or pending	√ _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√_None	
11	Stock or stock options	√_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√_None	
13	Other financial or non-financial interests	√ _None	

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

### Please place an "X" next to the following statement to indicate your agreement:

Date: 2	2021/3/2
<b>Your Nan</b>	ne:Xiaowu Dong
Manuscri	pt Title: Bruton's Tyrosine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tum	or Efficacy and Brain Distribution
Manuscri	int number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time fr	ame: Since the initial planning of the	work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.  Payment made to the institution.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	v_None	
3	Royalties or licenses	V_None	
4	Consulting fees	_v_None	

5	Payment or honoraria for	_v_None	
	lectures, presentations,		
	speakers bureaus, manuscript		
	writing or educational events		
6	Payment for expert testimony	√ None	
	, , ,		
7	Support for attending meetings	_v_None	
′	and/or travel		
	and/or traver		
_			
8	Patents planned, issued or	_V_None	
	pending		
9	Participation on a Data	_v_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	√ None	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock options	_v_None	
12	Receipt of equipment,	_V_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-financial	_v_None	
	interests		

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

### Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/3/2	
Your Name:Yizhe Wu	
Manuscript Title: Bruton's Tyrosine Kinase I	nhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tumor Efficacy and Brain Distribution	

Anti-tumor Efficacy and Brain Distribution Manuscript number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time fra	me: Since the initial planning of the wor	k
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.  Payment made to the institution.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	√_None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	√ _None √ _None
7	Support for attending meetings and/or travel	_ √ _None
8	Patents planned, issued or pending	√ _None
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ _None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ _None
11	Stock or stock options	√_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√_None
13	Other financial or non-financial interests	√_None

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021/3/2
Your Na	me:Yuxin_Zhuang
Manusci	ript Title: Bruton's Tyrosine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tun	nor Efficacy and Brain Distribution
Manusci	rint number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		me: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038)	Payment made to the institution.
	No time limit for this item.	Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√_None	
4	Consulting fees	√_None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	√ _None √ _None
7	Support for attending meetings and/or travel	_ √ _None
8	Patents planned, issued or pending	√ _None
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ _None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ _None
11	Stock or stock options	√_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√_None
13	Other financial or non-financial interests	√_None

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:	. 2021/3/2
Your Na	me:Shuiyun Han
Manuso	ript Title: Bruton's Tyrosine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tui	nor Efficacy and Brain Distribution
Manuso	ript number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plannin	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	None Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038)	Payment made to the institution.
	processing charges, etc.)  No time limit for this item.	Zhejiang Provincial Medicine and Health Science Fund(2021KY105)	Payment made to the institution.
		Time frame: past 36 mont	ths
2	Grants or contracts from any entity (if not indicated in item #1 above).	√ _None	
3	Royalties or licenses	√ _None	
4	Consulting fees	_ √ _None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	
7	Support for attending meetings and/or travel	_ √ _None
8	Patents planned, issued or pending	√ _None
9	Participation on a Data Safety Monitoring Board or Advisory Board	√ _None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√ _None
11	Stock or stock options	√ _None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√ _None
13	Other financial or non- financial interests	√ _None

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:_	_ 2021/3/2_										_
Your N	ame:Tao	Lei									_
Manus	cript Title: E	ruton's Tyro	sine Kinase	Inhibitors in	Primary	Central N	ervous Sy	stem Ly	mphoma-	–Evaluati	ion of

Anti-tumor Efficacy and Brain Distribution Manuscript number (if known): TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to
		none (add rows as needed)	you or to your institution)
	Time	frame: Since the initial planning of the	e work
1	All support for the present	None	
	manuscript (e.g., funding,	Science and Technology Program of	Payment made to the institution.
	provision of study materials,	Traditional Chinese Medicine,	
	medical writing, article	Zhejiang(2021ZB038)	
	processing charges, etc.)	Zhejiang Provincial Medicine and	Payment made to the institution.
	No time limit for this item.	Health Science Fund(2021KY105)	
		Time frame: past 36 months	
2	Grants or contracts from any	_v_None	
	entity (if not indicated in item		
	#1 above).		
3	Royalties or licenses	_v_None	
4	Consulting fees	_v_None	

_	De martin la comparta for	/ Nicos	
5	Payment or honoraria for	_v_None	
	lectures, presentations,		
	speakers bureaus, manuscript		
	writing or educational events		
6	Payment for expert testimony	_√_None	
7	Support for attending	_v_None	
	meetings and/or travel		
8	Patents planned, issued or	√ None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in	_√_None	
	other board, society,		
	committee or advocacy group,		
	paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	√ None	
12	materials, drugs, medical		
	writing, gifts or other services		
12		d None	
13	Other financial or non-	_v_None	
	financial interests		

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105).

The authors have no other conflicts of interest to declare.

### Please place an "X" next to the following statement to indicate your agreement:

Date: 2021/3/2	
Your Name:Haiyan Yang	
<b>Manuscript Title: Bruton's Tyro</b>	sine Kinase Inhibitors in Primary Central Nervous System Lymphoma—Evaluation of
Anti-tumor Efficacy and Brain D	vistribution
Manuscrint number (if known)	TCR-21-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments		
		have this relationship or indicate	(e.g., if payments were made to		
		none (add rows as needed)	you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present	None			
	manuscript (e.g., funding,	Science and Technology Program of	Payment made to the		
	provision of study materials,	Traditional Chinese Medicine,	institution.		
	medical writing, article	Zhejiang(2021ZB038)			
	processing charges, etc.)	Zhejiang Provincial Medicine and	Payment made to the		
	No time limit for this item.	Health Science Fund(2021KY105)	institution.		
		Time frame: past 36 months			
2	Grants or contracts from any	_v_None			
	entity (if not indicated in item				
	#1 above).				
3	Royalties or licenses	_v_None			
4	Consulting fees	_v_None			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	V_None
6	Payment for expert testimony	V_None
7	Support for attending meetings and/or travel	V_None
8	Patents planned, issued or pending	v_None
9	Participation on a Data Safety Monitoring Board or Advisory Board	v_None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_V_None
11	Stock or stock options	V_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	V_None
13	Other financial or non-financial interests	V_None

This work was supported by Science and Technology Program of Traditional Chinese Medicine, Zhejiang(2021ZB038) and Zhejiang Provincial Medicine and Health Science Fund(2021KY105)

The authors have no other conflicts of interest to declare.

# Please place an "X" next to the following statement to indicate your agreement: